The QualityStocks Daily Tuesday, May 16th, 2023

Today's Top 3 Investment Newsletters

QualityStocks(XELA) $6.2800 +103.90%

Schaeffer's(APRN) $0.5844 +27.13%

INO Market Report(ORMP) $3.8900 +24.28%

The QualityStocks Daily Stock List

Exela Technologies (XELA)

MarketBeat, QualityStocks, InvestorPlace, Schaeffer's, MarketClub Analysis, StockEarnings, BUYINS.NET, StocksEarning, StockMarketWatch, The Online Investor, StreetInsider, Trades Of The Day, Money Wealth Matters, The Street, TradersPro and INO Market Report reported earlier on Exela Technologies (XELA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Exela Technologies Inc. (NASDAQ: XELA) (OTC: XELAW) (FRA: 0Z1A) is a business process automation firm that operates as a global business process automation provider.

Exela Technologies provides digital business process, document management and enterprise information management services as well as transaction processing solutions. The firm also provides payment processing, print communications, digital mail rooms, unattended and attended cognitive automation and work flow automation.

Exela Technologies, which is based in Irving, Texas, was founded in 2017 and serves consumers across the globe. The firm operates through the following segments: Legal & loss prevention services, Healthcare solutions and Information & Transaction Processing Solutions.

The firm’s legal & loss prevention segment collects and distributes settlement funds, processes legal claims for mass action and class action settlement administration which involves project management support and outreach to claimants. Its healthcare segment offers information management for provider and healthcare payer markets, integrated accounts payable and accounts receivable and revenue cycle solutions while its information and transaction segment provides records management, benefits administration, benefits administration communications, claims processing, enrollments, casualty and property insurance solutions, sanctions, anti-money laundering, banking solutions for clearing and also lends solutions for auto loans and mortgages. Additionally, the firm provides revenue recovery services, expert witness services and analytical and data services in the area of statistical and economic analysis.

Exela Technologies was recently awarded a multi-million-dollar contract by a major U.S. health insurance company. This move will broaden the services Exela provides, which will extend the firm’s reach into new fields.

Exela Technologies (XELA), closed Tuesday's trading session at $6.28, up 103.8961%, on 54,838,888 volume. The average volume for the last 3 months is 3.337M and the stock's 52-week low/high is $2.62/$1359.60.

Leap Therapeutics (LPTX)

MarketClub Analysis, StockMarketWatch, QualityStocks, MarketBeat, TraderPower, StocksEarning, StockEarnings, Trades Of The Day, TradersPro, StreetInsider and BUYINS.NET reported earlier on Leap Therapeutics (LPTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Leap Therapeutics Inc. (NASDAQ: LPTX) (FRA: 5MC1) is a biopharmaceutical firm that is focused on the acquisition and development of new cancer treatments.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in 2011. Prior to its name change in November 2015, the firm was known as HealthCare Pharmaceutics Inc. It serves consumers across the globe.

The company's objective is to identify translational-stage molecules in the areas of immuno-oncology and cell signaling. It develops treatments that have been designed to treat cancer patients by harnessing their immune system to attack cancer cells and impede tumor-promoting pathways.

The enterprise's product pipeline is made up of a monoclonal antibody formulation dubbed DKM-01, which impedes the DKK1 protein. The protein, which is known as the Dickkopf-related protein 1, allows tumor cells to penetrate and spread, regulates signaling pathways and suppresses an individual’s immune system from attacking tumors. The formulation is in multiple clinical trials testing its effectiveness in treating prostate cancer, gynecologic cancers, hepatobiliary cancer and esophagogastric cancer. The enterprise's other clinical studies include P103, P205, P204, P102 and P100. In addition to this, the enterprise also develops an anti-glucocorticoid-induced tumor necrosis factor receptor monoclonal antibody dubbed TRX518, which has been developed to serve as the immune system’s checkpoint agonist.

The company recently presented positive data from its phase 2 clinical trial for its DKN-01 formulation used in combination with tislelizumab to treat gastroesophageal or gastric junction cancer. These promising results signal a possible treatment for this type of cancer on the horizon, which will not only benefit patients with this ailment but also bring in more investors into the company, which will be good for its growth.

Leap Therapeutics (LPTX), closed Tuesday's trading session at $0.5271, up 17.1333%, on 3,338,616 volume. The average volume for the last 3 months is 451,640 and the stock's 52-week low/high is $0.27/$1.86.

Cabaletta Bio Inc. (CABA)

QualityStocks, MarketBeat, TradersPro, StreetInsider, Zacks, InvestorsUnderground, InvestorPlace and FreeRealTime reported earlier on Cabaletta Bio Inc. (CABA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cabaletta Bio Inc. (NASDAQ: CABA) is a biopharmaceutical firm that is focused on discovering and developing T cell therapies for B cell-mediated autoimmune illnesses.

The firm has its headquarters in Philadelphia, Pennsylvania and was incorporated in April 2017 by Aimee Payne, Steven Nichtberger and Michael C. Milone. Prior to its name change in August 2018, the firm was known as Tycho Therapeutics Inc. The firm serves consumers in the United States.

The company explores the potential of engineered T cell therapies to offer a durable and curative treatment for these autoimmune ailments. Its technology uses cells that have been designed to bind to and eliminate disease-causing auto-antibodies.The company is party to a research agreement with The Regents of the University of California; and a collaboration agreement with the University of Pennsylvania.

The enterprise’s product pipeline comprises of a product dubbed DSG3/1-CAART, which has been developed to treat mucocutaneous pemphigus vulgaris; and a formulation known as FVIII-CAART, which has been developed to treat Hemophilia A. It also develops a preclinical stage product dubbed MuSK-CAART, to treat myasthenia gravis. In addition to this, the enterprise develops DSG3-CAART, which is undergoing a phase 1 trial evaluating its effectiveness in treating mucosal pemphigus vulgaris.

Recently, the firm announced its 2021 third quarter financial results, with its CEO noting that they were focused on providing a highly effective and possibly curative therapy without generalized suppression, for the treatment of mucosal pemphigus vulgaris. The success and approval of its DSG3-CAART formulation will bring in more investments into the firm while also providing effective treatment to patients suffering from this indication.

Cabaletta Bio Inc. (CABA), closed Tuesday's trading session at $13.16, up 14.6341%, on 452,367 volume. The average volume for the last 3 months is 36,781 and the stock's 52-week low/high is $0.59/$13.44.

Bion Environmental Technologies (BNET)

QualityStocks, MarketBeat, Wall Street Resources, SECFilings.com News, OTC Stock Review, TradersPro, TopPennyStockMovers and Stock Guru reported earlier on Bion Environmental Technologies (BNET), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bion Environmental Technologies Inc. (OTCQB: BNET) is a company focused on the development of patented and proprietary technology that offers waste treatment and resource recovery solutions for concentrated animal feeding operations (CAFOs).

The firm has its headquarters in Old Bethpage, New York and was incorporated in 1987, on December 31st by Jon Northrop and Jere Northrop. It operates as part of the pollution and treatment controls industry, under the industrials sector. The firm primarily serves consumers in the United States.

The company’s proven technology offers comprehensive treatment solutions that largely eliminate its environmental impacts while simultaneously recovering valuable assets from the waste stream, such as nutrients, renewable energy and clean water that have traditionally been wasted or underutilized. Its revenues are generated from the sale of nutrient reduction credits.

The enterprise’s offerings include Gen3Tech, a third-generation technology and business/technology platform that remediates environmental problems and improves operational/resource efficiencies through recovering co-products from the CAFOs' waste stream, including renewable energy, fertilizer products, and clean water. It focuses on the development of waste treatment facilities; licensing and/or joint venturing of its technology and applications; and installation of its systems to retrofit and environmentally remediate existing CAFOs.

The firm recently announced its intention to develop a sustainable cattle feeding operation, in collaboration with Dakota Valley Growers. This move will not only extend its reach but also open it up to new growth and investment opportunities. This is in addition to generating value for its shareholders.

Bion Environmental Technologies (BNET), closed Tuesday's trading session at $1.395, off by 0.711744%, on 36,781 volume. The average volume for the last 3 months is 15.184M and the stock's 52-week low/high is $0.505/$2.30.

Nokia Oyj (NOK)

FreeRealTime, The Street, InvestorPlace, MarketClub Analysis, StreetInsider, Schaeffer's, StocksEarning, MarketBeat, Kiplinger Today, Street Insider, Daily Trade Alert, StreetAuthority Daily, Trades Of The Day, SmarTrend Newsletters, Money Morning, INO.com Market Report, IT News Daily, The Online Investor, Marketbeat.com, Profit Confidential, Louis Navellier, Investopedia, InvestorGuide, Insider Wealth Alert, SiliconValley, The Motley Fool, TopStockAnalysts, internet, Trade of the Week, Penny Stock Rumble, TheStockAdvisor, Barchart, Daily Markets, Investor Guide, Investors Alley, MarketWatch, Market Intelligence Center Alert, Greenbackers, Wealth Insider Alert, TheStockAdvisors, Zacks, StockEarnings, Wyatt Investment Research, Wealth Daily, BUYINS.NET, The Best Newsletters, SmallCap Network, Stock Gumshoe, Penny Stock Buzz, Momentum Traders, Market FN, Top Pros' Top Picks, GorillaTrades, The Street Report, internetnews, ProfitableTrading, Trading Concepts, CRWEWallStreet, WStreet Market Commentary, Trading Markets, AllPennyStocks, Uncommon Wisdom, Investor Update, StockMarketWatch, Darwin Investing Network, Energy and Capital, Penny Detectives, CRWEFinance, FNNO Newsletters, Goldman Small Cap Research, Market Wrap Daily, FeedBlitz, Eagle Financial Publications, Dynamic Wealth Report, DrStockPick, BestOtc, BullDogReporter, PennyToBuck, MomentumBeats, Money and Markets, Taipan Daily, Navellier Growth, StockHotTips, The Growth Stock Wire, One Hot Stock, PennyOmega, The Wealth Report, QualityStocks, StockPicks, The Weekly Options Trader, Daily Profit, Daily Wealth, Daily Market Beat, Dividend Opportunities, Cabot Wealth, Terry's Tips, The Momentum Traders Network, TopPennyStockMovers, CRWEPicks, Super Stock Picker, CNBC Breaking News, StrategicTechInvestor, Wall Street Daily, Wall Street Greek, Broad Street, Bourbon and Bayonets, WallStreetBeats, Wallstreetbuzz, AnotherWinningTrade, WallstreetsHotteststocks, TradingMarkets, Stock Traders Chat, NanoCap Gems, 24/7 Trader, Market Intelligence Center, PickPennyStocks, iStockAnalyst, Research Driven Alerts, Shah's Insights & Indictments, smartOTC, Stock Research Newsletter, Stock Stars, Flagler Financial Group, Investing Daily, equities Canada, Stockdigest Report, Stockhouse, INO Market Report, Growing Stocks Reports, StockOrange, StockTwits, Michael Stone, StreetAuthority Financial, Oakshire News Bulletin, Streetwise Reports, Equities.com and Investing Futures reported earlier on Nokia Oyj (NOK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nokia Oyj (NYSE: NOK) (FRA: NOAA) (BMV: NOKN) is a company engaged in the provision of mobile, fixed and cloud network solutions.

The firm has its headquarters in Espoo, Finland and was incorporated in 1865 by Fredrik Idestam. It operates as part of the communication equipment industry, under the technology sector. The firm serves consumers around the globe.

The enterprise operates through the Mobile Networks, Network Infrastructure, Nokia Technologies and Cloud and Network Services segments. It provides products and services for radio access networks and microwave radio links for transport networks, and solutions for network management, as well as network planning, optimization, network deployment, and technical support services. It also offers fixed networking solutions, like Wi-Fi in-home solutions, fiber and copper-based access infrastructure, and cloud and virtualization services; IP networking solutions, including IP access, aggregation, and edge and core routing for mobile, residential, cloud, business and digital industry applications, as well as software-defined WAN solutions. This is in addition to offering a portfolio of optical networks comprising optical transport network switchers, portfolio coherent optical transponders, wavelength-division multiplexers, re-configurable optical add-drop multiplexer solutions, and optical line systems for metro access and aggregation, data center interconnect, regional, and long-haul/ultra-long-haul applications; and submarine networks. Furthermore, the enterprise provides business applications, which cover security, automation, and monetization; cloud and network services, including core network solutions, such as voice and packet core; cloud and cognitive services; and enterprise solutions covering private wireless and industrial automation.

The company remains committed to creating value with intellectual property and long-term research for its shareholders, in addition to better meeting its consumers’ needs.

Nokia Oyj (NOK), closed Tuesday's trading session at $3.95, off by 2.7094%, on 15,214,998 volume. The average volume for the last 3 months is 1,100 and the stock's 52-week low/high is $3.95/$5.28.

High Arctic Energy Services (HGHAF)

We reported earlier on High Arctic Energy Services (HGHAF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

High Arctic Energy Services Inc. (OTC: HGHAF) is an oilfield services firm that is engaged in the provision of oilfield services to exploration and production firms in Papua New Guinea and Canada.

The firm has its headquarters in Calgary, Canada and was incorporated in 1993. It operates as part of the oil and gas equipment and services industry, under the energy sector. The firm serves consumers around the globe.

The company operates through the Drilling Services, Production Services and Ancillary Services segments. The drilling services segment includes its drilling services in Papua New Guinea while the production services segment consists of the company's well-servicing and snubbing operations. On the other hand, the ancillary services segment refers to High Arctic's oilfield rental equipment in Canada and Papua New Guinea as well as its Canadian nitrogen compliance services.

The enterprise provides drilling services, which include the provision of drilling personnel; well servicing and snubbing services; and hydraulic workover units. It also rents oilfield equipment and offers nitrogen pumping units. This is in addition to owning and operating 2 heli-portable drilling rigs in Papua New Guinea. Furthermore, the enterprise offers support equipment, such as crawler cranes, rig matting, water pumps, telehandlers, forklifts/wheel loaders, lighting towers, camps, wash-down packages, trucks, vehicles, and drill pipes and BHA.

The firm, which recently released its latest financial results, remains committed to seeking opportunities for corporate transactions and growth that enhance value for its shareholders. This will, in turn, encourage more investments into the firm.

High Arctic Energy Services (HGHAF), closed Tuesday's trading session at $0.99, off by 0.801603%, on 1,100 volume. The average volume for the last 3 months is 108,741 and the stock's 52-week low/high is $0.7229/$1.49.

Byrna Technologies (BYRN)

MarketBeat, StocksEarning, StockEarnings, Trades Of The Day, TradersPro and MarketClub Analysis reported earlier on Byrna Technologies (BYRN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Byrna Technologies Inc. (NASDAQ: BYRN) is a non-lethal defense technology firm that offers non-lethal alternative solutions for law enforcement and private security.

The firm has its headquarters in Andover, Massachusetts and was incorporated in 2005, on March 1st. Prior to its name change in March 2020, the firm was known as Security Devices International Inc. It operates as part of the aerospace and defense industry, under the industrials sector. The firm serves consumers in the United States, Europe, Asia, South Africa, Canada and South America.

The enterprise provides handheld personal security devices and shoulder-fired launchers without the need for a background check or firearm license; and projectiles including chemical irritant, kinetic, and inert rounds. It offers self-defense aerosol products under the Byran Bad Guy Repellent brand; and accessories and related safety products, which include sighting systems, carbon dioxide canisters and holsters under the Byran Shield and Byran Banshee brand, as well as Byrna-branded apparel. Its product Byrna Shield is a ballistic-rated backpack that can be fitted with multiple armor panels that use a deployment system to protect the wearer from both the front and back. In addition to this, the enterprise provides the products to the consumer market through its Byrna e-commerce store and Amazon storefront, and network of local, regional and national outdoor and sporting goods stores, either directly or through distributors; and to the professional security market through its Train the Trainer program and de-escalation methods.

The company, whose latest financial results show increases in its revenues, remains committed to improving its operational efficiency and generating value for its shareholders.

Byrna Technologies (BYRN), closed Tuesday's trading session at $5.18, even for the day, on 109,229 volume. The average volume for the last 3 months is 5,700 and the stock's 52-week low/high is $4.50/$10.38.

Samsonite International (SMSOF)

The Street and Uncommon Wisdom reported earlier on Samsonite International (SMSOF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Samsonite International S.A. (OTC: SMSOF) is a company focused on designing, manufacturing, sourcing and distributing travel luggage bags.

The firm has its headquarters in Luxembourg, Luxemburg and was incorporated in 1910 by Jesse Shwayder. It operates as part of the footwear and accessories industry, under the consumer cyclical sector. The firm serves consumers around the globe.

The company operates through the North America, Asia, Europe, Latin America, and Corporate segments. The North America segment covers operations in Canada and the United States. The Asia segment covers China, India, Japan, the Middle East, Taiwan, Singapore, Malaysia, South Korea, Indonesia, Hong Kong, Thailand, Philippines, Australia, and certain other Asian markets. The Latin America segment includes Mexico, Chile, Brazil, Argentina, Peru, Colombia, Panama and Uruguay. The Europe segment represents European countries and the South Africa operations. On the other hand, the Corporate segment refers to certain licensing activities from brand names.

The enterprise offers luggage, business, computer, outdoor, casual, and women's bags; and travel accessories and slim protective cases for personal electronic devices primarily under the Tumi, Samsonite, High Sierra, American Tourister, Speck, Hartmann, Gregory, Kamiliant, Lipault and eBags brands, as well as other owned and licensed brand names. It sells its products through various wholesale distribution channels, as well as through company operated retail stores and e-commerce outlets.

The firm recently announced its latest financial results, which show increases in its sales. It remains committed to operating efficiently to better meet consumer needs, which will not only bring in additional revenues but also bolster its overall growth.

Samsonite International (SMSOF), closed Tuesday's trading session at $3, even for the day. The average volume for the last 3 months is 460,815 and the stock's 52-week low/high is $1.93/$3.216.

Alliance Resource Partners L.P. (ARLP)

The Online Investor, Zacks, QualityStocks, TradersPro, The Street, MarketBeat, InvestorPlace, MarketClub Analysis, Marketbeat.com, TopStockAnalysts, The Wealth Report, Dividend Opportunities, TheStockAdvisor, StreetAuthority Daily, The Motley Fool, Money Morning, DividendStocks, BUYINS.NET, Market Intelligence Center Alert, Early Bird, Daily Trade Alert, SmarTrend Newsletters, Daily Wealth, Rick Saddler, Wealth Insider Alert, Trading Concepts, The Growth Stock Wire, TheStockAdvisors, Investing Daily, TraderPower, TheOptionSpecialist, Insider Wealth Alert, Greenbackers, Eagle Financial Publications, Investment U, Daily Markets, FNNO Newsletters, Investor Update, PoliticsAndMyPortfolio.com, Louis Navellier, Trades Of The Day, Top Pros' Top Picks, MiningNewsWire, Money and Markets, TheTradingReport, TheStreet Offers, Short Term Wealth, StockEarnings, StreetInsider and Leeb's Market Forecast reported earlier on Alliance Resource Partners L.P. (ARLP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sources have revealed that India may be planning to halt construction of new coal-fired power plants by eliminating a certain clause from its National Electricity Policy. If the final draft of this policy is approved after this change is made, China would become the only economy in the world open to increasing its coal-fired capacity.

Currently, China and India make up roughly 80% of all active coal projects in the world. This comes at a time when most developing nations are reducing their capacity in an effort to meet their set climate targets to reduce CO2 emissions.

Data from E3G shows that as of January 2023, only 20 nations have more than a single coal project planned. One government source revealed that India had reached a decision to the effect that no more additions were needed. The sources also revealed that the amended electricity policy’s approval wouldn’t affect the coal-fired plants already in pipeline.

This move by the country is a welcome surprise, as India had repeatedly refused to set a timeline for phasing out coal, basing its argument on the demand for inexpensive sources of fuel, increasing renewable energy capacity and low per-capita emissions. Coal has been used to generate electricity in India for decades, but now with construction of new plants set to be halted, this will significantly reduce the fuel’s share in overall power output.

The country’s energy policy draft also suggests that the retirement of old coal plants be delayed, at least until energy storage for renewable energy becomes financially feasible. Thus far, old coal power plants with a total capacity of 13 GW have been tagged for decommissioning after the retirement deadline to meet high demand for power.

The first draft of the policy had, in 2021, included new coal-fired capacity, in addition to proposing new technology standards to help reduce pollution. India’s policy revision could also affect coal prices and miners in Australia, Indonesia and South Africa, as the country is the second largest importer of coal globally.

In contrast, the National Development and Reform Commission in China revealed in a document circulated last year that the country would proceed with the construction of coal-fired power plants based on development needs.

China is currently the largest consumer of coal globally. Together with India, the country lobbied against an end date for the use of coal. Now the East-Asian country has announced plans to construct 100 new coal-fired plants to help support solar and wind capacity. Analysts highlight that this doesn’t align with China’s stated intentions to reduce the role coal plays in power generation.

When major coal consumers such as India begin mulling regulatory changes to put an end to new coal plant construction, the writing is on the wall for companies such as Alliance Resource Partners L.P. (NASDAQ: ARLP) that time is running out and they need to rethink their future if they are to remain relevant in the evolving energy space.

Alliance Resource Partners L.P. (ARLP), closed Tuesday's trading session at $18.62, off by 2.9703%, on 484,191 volume. The average volume for the last 3 months is 964,912 and the stock's 52-week low/high is $16.43/$27.63.

Cenntro Electric Group Ltd. (CENN)

QualityStocks, TradersPro, GreenCarStocks, Penny Stock and InvestorPlace reported earlier on Cenntro Electric Group Ltd. (CENN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In 2022, Norway was at the forefront of the transition to battery-powered mobility owing to its 80% EV sales. Furthermore, Norway has become a research hub for analyzing how the electric car revolution can change the world. In 2025, the nation will stop selling ICE cars.

The experience of Norway demonstrates that EVs have advantages without having the negative effects that some detractors have projected. However, during moments of heavy demand, there are issues with faulty chargers and lengthy waits, and retailers and car dealerships have had to adjust. The switch has rearranged the auto industry, elevating Tesla to the top spot while pushing major brands, such as Fiat and Renault, to the sidelines.

Furthermore, the clean air in Oslo, the capital of Norway, is visible. As noise from petrol and diesel cars is eliminated, the city is likewise quieter. Oslo’s carbon dioxide emissions have decreased by 30% since 2009, but neither the power grid nor the gas station workforce has experienced any significant effects. The power grid is still operational.

Norway started to promote electric automobiles during the 1990s. In order to boost their uptake, BEVs were exempt from import and value-added taxes as well as from tollway taxes. In addition, the provision of subsidies by the government for the construction of rapid charging stations put Norway more than 10 years ahead of the United States. While the Biden administration has set a target for electric vehicle sales to make up 50% of all new vehicles sold by 2030, Norway already achieved that in 2019.

As more people buy electric vehicles, nitrogen oxide levels, byproducts of the combustion of petrol and diesel that result in asthma attacks and other illnesses, have significantly decreased.

However, the point where the rubber hits the road still presents a difficulty. The rubbing of asphalt and tires is a contributing factor to the harmful levels of tiny particles in the air in Oslo. The issue might be made even worse by electric cars, which make up roughly one-third of Oslo’s registered cars yet contribute to a larger amount of traffic, and they tend to be heavier than ICE comparable ICE vehicles.

Another issue that keeps coming up, according to those who live in apartments, is where to charge their cars. According to Sirin Hellvin Stav, the city intends to increase the number of public charging stations while also reducing the total number of vehicles by one-third in order to create safer roadways and provide more room for bicycling and walking.

The city of Oslo has a larger plan to cut its greenhouse gas emissions to nearly none by 2030. By year’s end, all buses in the city will be powered by electricity.

As EVs gain prominence and their uptake increases around the world, a time is coming when brands such as Cenntro Electric Group Ltd. (NASDAQ: CENN) and Tesla will be as commonplace as Toyota, GM and other legacy automakers were in their heydays.

Cenntro Electric Group Ltd. (CENN), closed Tuesday's trading session at $0.3558, off by 2.0374%, on 996,274 volume. The average volume for the last 3 months is 24,193 and the stock's 52-week low/high is $0.26/$2.27.

AmeriCann Inc. (ACAN)

QualityStocks, InvestorPlace, Promotion Stock Secrets, TopPennyStockMovers, Wall Street Mover, TheMicrocapNews, SmallCapVoice, Real Pennies, OTC Markets Group, MarketBeat and Cannabis Financial Network News reported earlier on AmeriCann Inc. (ACAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

AmeriCann (OTCQB: ACAN), a cannabis company that develops state-of-the-art cultivation, product manufacturing and distribution facilities, is reporting on its financial and operational results for the quarter ending March 2023; the report showed the company’s best-ever annual revenue and net income for its latest four quarters. According to the report, AmeriCann has reported five consecutive quarters of positive net income, with net income increasing 257% and revenue increasing an estimated 12% for the quarter ended March 2023 compared to the quarter ended March 2022. In the report, the company attributed the increased revenue to products produced and manufactured at the company's initial building at its Massachusetts Cannabis Center (“MCC”) development in Freetown, Massachusetts. The company noted that it is in the final design phase of expanding its MCC development, an initiative that has included securing provisional cultivation and manufacturing licenses. The next stage of expansion include adding up to 60,000 square feet of extraction, manufacturing and distribution infrastructure and approximately 160,000 square feet of additional cannabis cultivation infrastructure. “AmeriCann's financial discipline and strong business model have produced record profitability and cash flow," said AmericCann CEO Tim Keogh in the press release. “We achieved the best consecutive four quarters of revenue and net income in our history.”

To view the full press release, visit https://ibn.fm/GDXsB

About AmeriCann Inc.

AmeriCann is a cannabis company that develops cultivation, processing and product manufacturing facilities. AmeriCann uses greenhouse technology, which is superior to the current industry standard of growing cannabis in warehouse facilities under artificial lights. According to industry experts, by capturing natural sunlight, greenhouses use 25% fewer lights, and utility bills are reduced by as much as 75% compared to typical warehouse cultivation facilities. As such, AmeriCann’s Cannopy System enables cannabis to be produced with a greatly reduced carbon footprint, making the final product less expensive. Additionally, greenhouse construction costs are nearly half of warehouse construction costs. AmeriCann is also designing GMP-certified cannabis extraction and product manufacturing infrastructure. The company has secured provisional licenses to produce cannabis-infused products, including beverages, edibles, topicals and concentrates. AmeriCann plans to operate a marijuana product manufacturing business at the Massachusetts Cannabis Center. For more information about the company, please visit www.Americann.co.

AmeriCann Inc. (ACAN), closed Tuesday's trading session at $0.237, up 13.9423%, on 24,193 volume. The average volume for the last 3 months is 1.947M and the stock's 52-week low/high is $0.08/$0.463.

Guardforce AI Co. Limited (GFAI)

QualityStocks, Timothy Sykes, The Stock Dork, Schaeffer's, 360wallstreet, Money Wealth Matters, MarketClub Analysis, INO Market Report, Wall St. Warrior, PennyPro, InvestorPlace and 247 Market News reported earlier on Guardforce AI Co. Limited (GFAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Guardforce AI (NASDAQ: GFAI, GFAIW), an integrated security provider specializing in secured logistics, AI and Robot-as-a-Service (“RaaS”), has announced the closing of its underwritten public offering of 2,580,600 ordinary shares, par value of $0.12 per share, each at a public offering price of $4.65. The underwriters exercised the over-allotment option in full for an additional 387,090 ordinary shares at the time of the closing. As a result, Guardforce AI secured aggregate gross proceeds of approximately $13.8 million prior to deducting underwriting discounts and other offering expenses. EF Hutton, division of Benchmark Investments LLC, acted as the lead book-running manager and Spartan Capital Securities LLC acted as the co-manager for the offering.

To view the full press release, visit https://ibn.fm/TRXO8

About Guardforce AI Co. Limited

Guardforce AI is a global security solutions provider, building on its legacy secured logistic business while expanding and transforming into an integrated AI and Robot-as-a-Service (“RaaS”) business. With more than 40 years of professional experience and a strong customer foundation, Guardforce AI is developing RaaS solutions that improve operational efficiency, quickly establishing its presence in the Asia Pacific region, while expanding globally. For more information, visit www.GuardforceAI.com.

Guardforce AI Co. Limited (GFAI), closed Tuesday's trading session at $5.1, up 3.2389%, on 2,016,340 volume. The average volume for the last 3 months is 32,771 and the stock's 52-week low/high is $3.81/$36.8999.

The QualityStocks Company Corner

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria just awarded InClin, Inc. the contract for CRO services, in a move that lines up with the company's upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1

InClin will manage the study in the form of clinical site evaluation and selection, project management, personnel, site training, and more

Patient dosing is set to kick off as soon as possible once the expected FDA IND filing and review is completed, which Lexaria hopes will be done this summer

HYPER-H23-1 will be Lexaria's most ambitious study yet, and upon its completion, it will move the company closer to FDA approval of its patented DehydraTECH(TM)-processed CBD

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the awarding of the contract for clinical research organization ("CRO") services to California-based InClin, Inc. This move is in line with the company's upcoming Food and Drug Administration ("FDA")-registered, U.S. Phase 1b Investigational New Drug ("IND") hypertension study, HYPER-H23-1 that will explore the potential of its patented DehydraTECH(TM)-processed cannabidiol ("DehydraTECH-CBD") for the treatment of hypertension (https://cnw.fm/8WGqS).

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $0.74, up 2.0971%, on 32,772 volume. The average volume for the last 3 months is 215,627 and the stock's 52-week low/high is $0.705/$3.60.

Recent News

Data443 Risk Mitigation Inc. (OTC: ATDS)

The QualityStocks Daily Newsletter would like to spotlight Data443 Risk Mitigation Inc. (OTC: ATDS).

Data443 Risk Mitigation (OTC: ATDS ), a data security and privacy software company for "All Things Data Security," is reporting on its results for the quarter ended March 31, 2023. Financial highlights of the report include 125% increased revenue year over year, 184% increased gross profit year over year and a 60% decreased net loss year over year. Business highlights for the year include a 98% customer renewal rate, the VB100 certification of Data443(R) Antivirus Protection Manager(TM), and the company's Ransomware Recovery Manager being named Best of Inexpensive Protection and Best for Kiosks in PCMag's The Best Ransomware Protection for 2023. In addition, the company inked an additional contract from one of its largest fintech clients and signed a contract with a long-time, multinational fintech client that provides payment technology and services to merchants, issuers and consumers. ATDS also added a $484,000 contract with one of the "Big Four" U.S.-based banks and released an update to its award-winning Ransomware Recovery Manager product.

"Our first-quarter results are a testament to our team's relentless drive, passion and commitment to better serving our existing enterprise clients and expanding our market reach," said Data443 founder and CEO Jason Remillard in the press release. "Our 125% revenue growth from a year ago clearly indicates that our efforts are resonating with our clients and the trust they place in us. We have attracted new customers while retaining existing ones, and we are further validated by our high customer renewal rates and eagerness to renew with larger and longer-term contracts. This has always been the ultimate vote of confidence in our company. We are proud of the relationships we have built with our customers and will continue to nurture these partnerships in the years to come. While we believe these strong Q1 results reflect that our business plan is working, we recognize that there is still work to be done. As we announced yesterday, we entered into a definitive agreement to acquire select assets from Cyren Ltd. We certainly understand what it takes to integrate acquisitions and onboard new customers to Data443, and we are very excited about the opportunities ahead of this important transaction."

To view the full press release, visit https://ibn.fm/vxWCs

Data443 Risk Mitigation Inc. (OTC: ATDS) is a data security and privacy software company for ALL THINGS DATA SECURITY™. The company is committed to organizing the world’s information by identifying and protecting all sensitive data regardless of location, platform or format.

Data443 provides software and services to enable secure data across devices and databases – at rest and in transit – locally, on a network, or in the cloud. With over 10,000 customers in more than 100 countries, Data443 provides a modern approach to data governance and security. The company’s framework helps customers prioritize risk, identify security gaps, and implement effective data protection and privacy management strategies.

Data443 derives revenue primarily from contracts for subscriptions to access its SaaS platforms, and ancillary services provided in connection with its subscription services. In today’s ever-changing environment with unique and complex requirements for data privacy, governance and hybrid workforces, every organization needs to know where all their data is, who has access to it and how sensitive it is. Data443 provides the tools needed to give companies control over their data processing activities, with capabilities for identifying, reporting and migrating or deleting sensitive data.

The company is headquartered in Research Triangle Park, North Carolina.

Products

Focused on data security with a privacy-forward methodology, the Data443 product suite delivers solutions designed to securely manage data and data privacy needs on-premises, in the cloud and in hybrid environments. Offerings include:

  • Data Identification Manager reduces risk by shining a light on dark data across cloud, on-premises and hybrid environments. From a centralized dashboard, Data Identification Manager provides the ability to automatically inventory all data repositories, classify and tag all data, and enable global search and discovery – all through an agentless deployment.
  • Data Placement Manager quickly and securely transfers sensitive data over any public or private network. Available as an HP Nonstop server-based application and for Windows, Linux or any public cloud provider, Data Placement Manager enables the scheduling, routing, formatting and transfer of business-critical data.
  • Data Archive Manager is an “all information, anywhere” archiving solution designed to handle and manage all types of privacy requests across cloud, on-premises and hybrid environments. With over 15 years operational history and hundreds of clients managing millions of mailboxes, the platform is purpose-built for information archiving, retention and privacy request management.
  • Data Hound™ is a data discovery, classification and capture toolset that enables organizations to perform quick scans, detailed reporting and subsequent data actions based on policy.
  • Ransomware Recovery Manager is the only industry solution that actively recovers the device, operating system and data with a simple reboot. Using patented, proven technology, the product produces 100% effectiveness for the whole device and datasets.
  • Access Control Manager provides user ID and passwordless access to quickly enable trust across an organization’s entire ecosystem. Its unique architecture allows it to leverage multiple distributed authoritative sources to understand and resolve a typical access request – with the ability to enable or deny the action on the fly.
  • Global Privacy Manager provides organizations one comprehensive view, for all privacy requirements, across all enterprise data, all at once. This unmatched visibility into an organization’s data assets ensures that all private and sensitive data can be identified and protected and that enterprises can obey all relevant privacy laws in any jurisdiction.
  • Sensitive Content Manager is a security-centric collaboration service designed to give organizations the tools needed for successful content sharing, collaboration and safe distribution with full enterprise management in mind. With a continuous sync feature, encrypted data is automatically downloaded and updated in real time – regardless of location – ensuring that users have the most accurate data available.

Market Outlook

A report from Allied Market Research estimates that the global data security market was worth about $19 billion in 2021 and is projected to reach a value of $54.23 billion by 2027. That represents a CAGR of more than 18% for the forecast period, making data security one of the hottest areas within IT.

Separately, Fortune Business Insights estimates the global data privacy software market is valued at $2.36 billion in 2022 and projects it will grow to $25.85 billion by 2029. That represents a CAGR of 40.8% over the forecast period.

Management Team

Jason Remillard is President, CEO and Founder of Data443. He is responsible for overseeing global expansion, management, execution and corporate development. With over 25 years in global enterprise and B2C software sales and marketing, he brings deep leadership and technical experience, having spent previous time at Fortune 500 companies such as Deutsche Bank, TD Bank, IBM & Merrill Lynch.

Greg McCraw is CFO at Data443. He has over 25 years of experience helping businesses strengthen their accounting and finance operations. He previously served as Vice President of Finance for a dental services organization active in acquisitions, and, prior to that, he was managing director of a boutique accounting and finance consulting firm advising Fortune 500 clients in pharmaceutical, financial services, and private equity sectors on how to execute on regulatory and compliance solutions.

Bennett Pursell is Data443’s Chief Technology Officer. He has over 20 years of experience in IT architecture, security governance and systems integration. Prior to his role at Data443, he served as Head of Technology Architecture at Moody’s Investor Services and was Vice President and Technical Architect of Cloud Computing at Deutsche Bank, along with a host of technical and project management roles dating back to 2006, after starting his career as a web developer with a few startups and running research labs.

Kirill Kashigin is Chief Software Architect at Data443. He leads the development and quality teams, and serves as technical adviser and subject matter expert, bringing vast technical knowledge on privacy management and data security. Formerly the CTO of FileFacets, he has nearly 20 years in development of high-performance systems and deployment.

Data443 Risk Mitigation Inc. (OTC: ATDS), closed Tuesday's trading session at $0.0419, up 44.4828%, on 215,627 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.60/$.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

The illegal cannabis trade in California is so tenaciously entrenched that it not only undercuts the legal market but is also responsible for some of the most flagrant water theft in the whole world. The estimated $8 billion illegal marijuana sector uses astonishing amounts of the scarce resource, despite the state legalizing recreational marijuana in 2016.

It has been reported that some individuals haul in stolen water, while others steal it from fire hydrants or dig unauthorized wells. The issue has been made worse by years of intermittent drought in the state. John Nores, the former head of the California Department of Fish and Wildlife Marijuana Enforcement Team, described the quantity of water stolen by the illegal marijuana sector as "mind-blowing."

Nores estimates that it takes a typical marijuana plant 90 to 275 days to mature, and the plant needs up to five gallons of water every day. That's a lot of water when you consider that some illegal businesses are growing 2,000 to 5,000 plants on average. As the water crisis worsens, licensed growers may need to explore a variety of cultivation techniques, such as indoor microgardens commercialized by companies such as Advanced Container Technologies Inc. (OTC: ACTX), to maximize the value that they obtain from the limited water resources currently available.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Tuesday's trading session at $0.3, even for the day, on 51 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.073/$1.00.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

Beckley Psytech is a clinical-stage biotechnology company focused on improving the lives of individuals living with neuropsychiatric disorders through the development of psychedelic drugs. In its latest press release, the company revealed that it has administered a new intranasal psychedelic using an FDA-approved delivery device to a patient with treatment-resistant depression during a phase 2a trial.

The objective of the phase 2 trial is to assess the effectiveness, safety and pharmacokinetics of the company's BPL-003 formulation when administered together with psychological support, to patients experiencing moderate to severe symptoms of treatment-resistant depression. BPL-003 is a synthetic formulation of the 5-MeO-DMT compound.

It is estimated that roughly 3.8% of the global population suffers from depression, which adds up to about 280 million individuals. Treatment-resistant depression (refractory depression) is used to describe individuals suffering from major depressive disorder who don't respond to antidepressant medications. This particular clinical trial is just one of the many ongoing or planned psychedelic studies that numerous entities such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are financing in order to explore how best these substances can be harnessed for human health.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Tuesday's trading session at $0.00454, even for the day, on 50 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0031/$0.0649.

Recent News

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW)

The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

NextPlat Corp. (NASDAQ: NXPL), a global e-commerce provider, is reporting on its financial results for the three months ended March 31, 2023. The report also noted that the company is looking to drive future growth by adding healthcare and an Alibaba Tmall Global partnership. Financial highlights for first quarter of 2023 include revenues of approximately $2.9 million, an increase of 26% from the core revenue reported in Q1 2022 after accounting for several factors; gross margins of 21.6%; operating expenses totaling approximately $1.9 million; net loss for the quarter coming in at $1.2 million; and approximately $16.7 million in cash. Business highlights outlined in the report include the company's Global Telesat Communications Ltd. business unit being selected by Iridium Communications Inc. as a new direct distributor and global launch partner; the introduction of more than 100 new products; and the launch on April 24, 2023, of the company's e-commerce development program enabling Florida-based businesses to quickly access global international markets in Asia.

In addition, the report noted that on April 13, 2023, NextPlat completed a private offering of its common stock resulting in net proceeds of $6 million. "First-quarter results demonstrate the early benefits and value of our recent investments into NextPlat's global e-commerce infrastructure, which has allowed us to enter 2023 with a greatly enhanced capability on a global scale," said NextPlat CEO and executive chair Charles M. Fernandez in the press release. "These capabilities provide critical support for our continued efforts to expand our global addressable markets through new partnerships with Alibaba's Tmall Global and add an array of new customers across high-growth sectors including healthcare and consumer products."

To view the full press release, visit https://ibn.fm/DwVne

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Alibaba.com Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Tuesday's trading session at $2.47, off by 11.1511%, on 40,104 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.2115/$4.26.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting its financial results for the first quarter ended March 31, 2023; the report also noted key business updates. Highlights of the report indicate R&D expenses for quarter totaled $2 million with marketing, general and administrative expenses for the quarter reaching $1.2 million and total operating expenses coming in at $3.2 million, compared with $2.6 for same period in 2022. The report noted financial (loss) income for the quarter totaling $(0.3) million compared with $0.14 million for the three months ended March 31, 2022, and net loss of $3.5 million compared with $2.47 million for the three months ended March 31, 2022. Business highlights include the company offering its cGMP manufacturing capabilities to interested parties and reporting positive preclinical in vivo data indicating its innovative inhaled anti-SARS-CoV-2 NanoAb virtually prevented illness when administered prophylactically. The company also attended the several key conferences during the quarter.

To view the full press release, visit https://ibn.fm/wpVY9

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Tuesday's trading session at $1.81, off by 0.995515%, on 7,936 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.70/$14.10.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Scientists have found a new way to detect tumors in the brain using a device that picks out a certain protein in the urine. This noninvasive method will eliminate the need for invasive tests while also increasing the chances of tumors being detected earlier.

Glioblastoma multiforme is a common and very aggressive brain cancer that causes malignant brain tumors to develop. Common symptoms include blurry vision, recurring headaches and unusual changes in personality or mood.

Tumors in the brain are often detected after neurological symptoms such as loss of speech or movement start to present. By the time these are showing, the tumor may have already grown considerably. Experts believe that the best way to improve survival rates for brain cancer is to find ways to detect the tumors early, which will in turn give the treatment a longer time to take effect. The possibility of detecting deadly brain cancers through running urine tests, as well as the numerous drug-development efforts being undertaken by enterprises such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP), suggest that a time is coming when cancer patients' clinical outcomes will be a lot better than they currently are.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $1.24, off by 10.7914%, on 222,238 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6105/$11.304.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, has released a financial update for its fiscal second quarter for the three and six months ended March 31, 2023. According to the report, the company used $67.6 million cash in operating activities, with cash flows used in investing activities coming in at $97.4 million; those numbers are offset by cash inflows from financing activities of $167.4 million for the six months ended March 31, 2023. The report noted that net loss before accrued preferred dividends and noncontrolling interest came in at $495.4 million for the six-month period, with noncash charges totaling $426.4 million and operating asset and liability charges reaching $1.4 million for the same period. The report showed an estimated $86.3 million in cash available for operations and investment on March 31, 2023, with that number increasing to approximately $116.1 million as of April 30, 2023. The report also noted that an additional committed capital of $45 million should before received by the end of June. "We are pleased with the accomplishments and progress made during our fiscal second quarter of 2023," said Mullen Automotive CEO David Michery in the press release. "Mullen remains committed to delivering innovative and sustainable transportation solutions to our customers, and these achievements reflect our dedication to advancing the EV industry and driving meaningful growth for our company. . . . With a solid financial position, a robust product lineup and strong strategic partnerships, Mullen is well positioned to continue its trajectory and deliver cutting-edge EVs to the market."

In addition, Mullen is also reporting that the first of its class 3 trucks has been delivered to North-Carolina-based Randy Marion Automotive, MULN's dealer partner; the truck will be used for customer test drives and demonstrations. Priced at $68,500, the Mullen THREE features an estimated 130-mile range and 5,800-pound payload; the vehicle can also carry a 14-foot box and has more than 1,000 cubic feet of cargo capacity. "It is exciting to enter the next phase of our commercial launch with the Mullen THREE — the customers, piloting, testing and evaluation stage," said Mullen chief commercial officer John Schwegman in the press release. "Demand has been strong since we introduced this product and the aggressive price point. We are excited to get customers behind the wheel of our Class 3 product."

To view the full press releases, visit https://ibn.fm/0c5TW and https://ibn.fm/9j507

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $1.22, off by 2.4%, on 21,914,101 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.18/$42.75.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue light emergency communication systems, today released the transcript and video of its First Quarter Town Hall Update that occurred at 1 p.m. PT on May 15, 2023. In the update, the company's CEO William Santana Li reviewed financial highlights from Knightscope's recently filed quarterly report on Form 10-Q for the first quarter 2023, as well as shared current events that may be of interest to stockholders and potential investors.

"First, I am pleased to report that for the 1st quarter of 2023, we recorded approximately $2.9M in revenue over the first three months of the year, which is an over 300% improvement over the 1st quarter of 2022. This included a year-over-year increase in service revenue of approximately 85%. Service revenue includes our ASR Machine-as-a-Service revenue as well as maintenance and support revenue related to the blue light towers and call boxes, which was the primary driver of the significant increase as compared to the first quarter of 2022," Li stated in the update. "We plan to continue growing the company, and we believe our sales pipeline is strong, and increasing sales will allow us to grow, drive economies of scale, and better leverage our fixed cost base."

To watch the recorded portion of the Town Hall, visit www.knightscope.com/rise, scroll to the Rise of the Robots section and select Episode 6.

To view the full press release, visit https://ibn.fm/p1QmF

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.knightscope.com/crime

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at www.knightscope.com/investors

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at www.knightscope.com/ksoc

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at www.knightscope.com/roadshow

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Tuesday's trading session at $0.4997, off by 12.5634%, on 1,536,982 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.49/$4.5197.

Recent News

CISO Global, Inc. (NASDAQ: CISO)

The QualityStocks Daily Newsletter would like to spotlight CISO Global, Inc. (NASDAQ: CISO).

CISO Global Inc. (NASDAQ: CISO), a Scottsdale, Arizona-based industry leader as a managed cybersecurity and compliance provider, has named Chief Financial Officer Deb Smith to its board of directors. Smith has served as the CFO and secretary since 2021. "Deb has overseen and managed the complex financial aspects of successfully acquiring and integrating 17 companies on a global basis," said David Jemmett, CEO and founder of CISO Global. "She is a trusted member of our executive team and brings tremendous leadership and perspective to our board."

In addition, CISO Global announced that it has formed vCISO LLC to own and out-license certain intellectual property of the company. According to the update, the ARGO Security Management Platform will be the first asset moved to the wholly owned subsidiary. "Over the course of 17 acquisitions, we have brought together some amazing talent that has developed game-changing security solutions," CEO David Jemmett said in the news release. "We have been enhancing, testing and deploying these solutions to ensure their efficacy and efficiency."

To view the full press releases, visit https://ibn.fm/KptRR and https://ibn.fm/pu4i1

CISO Global, Inc. (NASDAQ: CISO) is an industry leader in cybersecurity and compliance services. The company leverages an integrated approach to reduce noise and bridge common silos that often limit the effectiveness of cybersecurity programs. Pulling disparate technologies, teams, and vendors together, CISO helps its clients enjoy a simpler and more successful journey to cyber resilience. Since 2019, CISO Global has worked to rapidly expand by acquiring world-class cybersecurity and compliance businesses with top-tier talent who utilize the latest technology to create innovative protection solutions.

The CISO Global workforce is comprised of cybersecurity experts spanning not only global geographies, but also specialties, industries, regulatory frameworks and focus areas. Its team includes audit and compliance specialists, certified forensics experts, ethical hackers, IEEE® certified biometric professionals, security engineers, around-the-clock analysts, and more – all backed by the most respected credentials in the industry. On an ongoing basis, the company works to identify cyber talent that is culturally aligned and that offers operating leverage through both existing customer revenue and relationships.

CISO Global has invested in enterprise solutions and executive talent to integrate its different organizations into an ecosystem that works together to provide complete cybersecurity through cross-pollination of solutions that begin at the network level and extend through technologies, people, policy, and practices. This ecosystem is intended to foster additional growth opportunities and drive overall recurring revenue. Once engaged, the company strives to become trusted advisors for customers’ cybersecurity and compliance demands by providing tailored security solutions based upon their organizational needs.

While cyber resilience requires cycles of continuous improvement, it is a journey that few in the current business and security climate seem to understand. With its deep bench of seasoned experts, CISO Global works to simplify that journey for its growing customer base, straightening out the curves and speeding up the process to resilience along the way.

Cybersecurity is a Culture, Not a Product

Integrating compliance and security, including principles of security by design, CISO Global helps its clients create an organization-wide culture of cybersecurity. Its offerings include audit and compliance, security operations center services, security engineering, virtual Chief Information Security Officer services, incident response, certified forensics, technical assessments and cybersecurity training.

In contrast to the majority of cybersecurity firms that specialize in a specific technology or service, CISO Global seeks to differentiate itself by remaining technology agnostic, focusing on accumulating highly sought-after subject matter experts. CISO Global believes that bringing together a world-class team of technological experts with multi-faceted proficiency in the critical aspects of cybersecurity is key to providing technology agnostic solutions to its clients in a business ecosystem that suffers from a chronic lack of highly skilled professionals.

CISO Global’s goal is to create a culture of security and to help quantify, define and capture a return on investment from information technology and cybersecurity spending. Its end-to-end, holistic process covers every aspect of clients’ cybersecurity and compliance requirements in an effort to promote greater efficiency and strengthen awareness about the integral role of internal team members in the cybersecurity culture of an organization.

As a result of this strategy, CISO Global customers receive an efficient engagement from a single partner that covers a wide range of their needs – addressing challenges more thoroughly and resolving problems more rapidly when compared to working with a host of vendors.

Market Outlook

According to an analysis by the firm Research and Markets, the global managed security services market was valued at $22.45 billion in 2020 and is projected to reach $77.01 billion by 2030, growing at a CAGR of 12.8% through the forecast period.

An expected increase in cybercrime, cost effectiveness of provided solutions and stringent mandatory government regulations aimed at protecting corporate data will drive the global managed security services market for the foreseeable future.

In addition, the documented and growing use of mobile devices in the workplace and the rise in captured and stored digital data serve to fuel market growth. Moreover, growing awareness about the critical nature of data security, the growing importance of e-business and demand for customized services is expected to offer ample opportunities for expansion of the market during the forecast period.

Management Team

David Jemmett is CEO and founder of CISO Global. He has more than 35 years of executive management and technology experience with telecommunications, managed services, and cybersecurity consulting services. He previously held positions as CEO of GenResults, a leading provider of security consulting services and technology solutions, and as CTO and founder at ClearData Networks, a HIPAA-compliant HealthDATA cloud hosting platform.

Dave Bennett is COO at CISO Global. Since 2015, he has served on the President’s STEM Advisory Board of Grand Canyon University. Before joining CISO Global, he served as Chief Product Officer at Experian Health and as Senior Vice President, Product for Gainwell Technologies. He has also held positions as Vice President and Worldwide Head of Build, Healthcare and Life Sciences at DXC Technology, and as EVP, Product and Strategy at Orion Health.

Ashley Devoto is President and Chief Information Security Officer at CISO Global. Over the past 17 years, Devoto has worked with the cybersecurity elite to design, build, and operate world-class cybersecurity programs for large, diverse organizations in both government and commercial enterprises. Prior to joining CISO, Devoto served as CISO for Booz Allen Hamilton, as business information security officer (BISO) at Bank of America, and as a cyberspace operations officer in the United States Air Force.

Deb Smith is CFO at CISO Global. Prior to assuming that position, she was the company’s EVP, Finance and Accounting. She has also served as SVP, Global Accounting at International Cruise and Excursions Inc., and as Chief Accounting Officer for BeyondTrust, an information security software company. She has also held the positions of Corporate Controller at Aspect Software and Assistant Controller at JDA Software.

CISO Global, Inc. (NASDAQ: CISO), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF)

The QualityStocks Daily Newsletter would like to spotlight Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF).

Reflex (CSE: RFLX) (OTC: RFLXF) (FWB: HF2) today announced a partnership with Lone Star Tech Minerals ("LSTM"), a Texas-based graphite and industrial minerals marketing consulting firm, which will assist Reflex with competitive analysis, market research and marketing strategies. Under the partnership, LSTM will provide Reflex with a strategic production and marketing plan. "We are excited to partner with Lone Star Tech Minerals and leverage their marketing and technical experience," said Paul Gorman, CEO of Reflex Advanced Materials Corp. "Lone Star's extensive knowledge of the CSPG industry will be invaluable as we aim to deliver high-quality, custom graphite products to a wide range of industry uses and chemistries to the North American supply chain."

To view the full press release, visit https://ibn.fm/MoIjd

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developing economic properties in the strategic metals and advanced materials space. The company aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications.

Reflex Advanced Materials is based in Vancouver, British Columbia. Its project portfolio includes the Ruby Graphite Deposit in Montana and the ZigZag Lithium Property in Ontario.

Projects

Ruby Graphite Project

Located in a mining-friendly jurisdiction in southwest Montana, the Ruby Graphite Deposit is a low cost, rapid re-entry opportunity that produced roughly 2,400 tons of graphite from 1902 to 1948. Reflex Advanced Materials holds mining rights for 755 hectares at the Ruby Graphite Project, with 96 federal lode mining claims. Recent samples assay at 95.8% to 98.4% total carbon.

The site is notable as the only combined U.S. graphite flake and vein graphite source. Vein graphite is ideal for energy storage applications, because it requires fewer steps to achieve purity than synthetic alternatives and is therefore far less environmentally damaging. This is expected to play a key role in the project’s development as demand for electric vehicles continues to surge.

In March 2023, the company announced its submittal of permit applications to the Bureau of Land Management in respect of its exploration of the Ruby Graphite Project. Its initial drill program, expected to take place in the summer of 2023, includes plans for 3,500 total meters of drilling, cored to an average depth of 130 meters. The targets for this drill program have been identified using historical data from original mine operations and data gathered for the initial 43-101 technical report on the project, dated January 31, 2023.

ZigZag Lithium Property

Located in the Thunder Bay Mining Division of Ontario, the ZigZag Lithium Property consists of eight mining claims spanning roughly 2,710 hectares. Mineralization at the property, most notably lithium, is based in pegmatite dikes and concentrated in spodumene crystals, which are consistent throughout the entire unit.

Spodumene is readily observable in outcrops and in drill cores, with crystal sizes ranging from 3-15cm, on average.

Reflex Advanced Materials and American Energy Technologies Company Metallurgical Partnership

Reflex Advanced Materials has entered into a material processing agreement with American Energy Technologies Co., which is based in Arlington Heights, Illinois, to conduct metallurgical testwork with the goal of creating a technical support data package for Reflex’s target customer base, U.S. Federal agencies and qualification programs with hi-tech customers in the battery and battery storage business.

The resulting coated, spherionized, purified graphite (CSPG) material that is expected to be created from the aforementioned tests will be used to provide potential customers of CSPG with samples so that they can begin the material qualification process.

Market Opportunity

Graphite is an ideal battery anode and has dominated the market since the proliferation of lithium-ion batteries. Despite this demand, there is currently no significant production of lithium-ion battery anode material in North America.

Instead, most graphite sold in North America today is sourced from Chinese producers. U.S. President Joe Biden highlighted this sourcing disparity in a 2022 address:

“The United Stated depends on unreliable foreign sources for many of the strategic and critical materials necessary for the clean energy transition – such as lithium, nickel, cobalt, graphite and manganese for large-capacity batteries,” he said. “Demand for such materials is projected to increase exponentially as the world transitions to a clean energy economy.”

The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles and combat this foreign dependency. Reflex Advanced Materials has identified its Ruby Graphite Project as a prime candidate for U.S.-sponsored initiatives due to the rarity and scarcity of natural graphite deposits in the country.

Processing graphite domestically in the U.S. is expected to provide Reflex Advanced Materials a competitive advantage as manufacturers begin to seek out American supply in the face of increased diplomatic tension. This is critical, as a rise in anode demand is expected to fuel a shortage of 8 million tonnes of graphite by 2040. World Bank Group projects 494% growth in total graphite demand by 2050.

Leadership Team

Paul Gorman is the CEO and a Director of Reflex Advanced Materials. He brings to the company over 25 years of experience in junior mining finance, public listings, viability assessment and operational rationalization. For 18 years, Mr. Gorman served as president and managing partner of Riverbank Capital, where he played an instrumental role in raising more than $85 million for small-cap companies. In 2008, he funded Industrial Minerals Inc. (later Northern Graphite) and served in an advisory role for four other graphite companies, contributing significantly to the revitalization of the junior graphite space in North America. Mr. Gorman founded Mega Graphite Inc. in 2009 and has served as chief executive for three other companies.

Tasheel Jeerh, CPA, is the company’s CFO. He is a finance and accounting professional with over a decade of experience spanning both public and private sectors. Prior to joining Reflex Advanced Materials, Mr. Jeerh played a pivotal role in the growth of a private upstream oil and gas firm, dealing with over $2 billion in M&A activity and $1 billion in financing activities. He gained his designation at PricewaterhouseCoopers, where he worked as a manager in the assurance practice.

Greg Bell is Project Manager for Reflex Advanced Materials. He is a multi-disciplined engineering management professional with more than 40 years of experience in the natural resources sector. Mr. Bell has successfully built and managed several start-up operations in various capacities. He has been active in graphite and lithium exploration for the past seven years.

Christopher W. Hill leads the company’s Corporate Development initiatives. He is an investor and entrepreneur with over a decade of experience in the capital markets. Mr. Hill began his career as an investment advisor and then began to consult and advise private companies on their paths to becoming publicly traded. He specializes in corporate development and strategic financing utilizing his large network in the capital markets.

Reflex Advanced Materials Corp. (RFLXF), closed Tuesday's trading session at $0.2986, off by 0.466667%, on 231,965 volume. The average volume for the last 3 months is 231,965 and the stock's 52-week low/high is $0.25/$0.765.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (OTCQB: SHRG) and DSS Inc. (NYSE American: DSS) recently announced the distribution date for the common stock of Sharing Services that is beneficially held by DSS directly and through its subsidiary, Decentralized Sharing Systems Inc. ("DSSI"). According to the announcement, each share of DSS common stock outstanding as of 5 p.m. ET held on April 28, 2023, entitled the holder to receive two SHRG common stock shares distributed on May 4, 2023. As a result, DSS and DSSI hold an approximate 7% ownership interest in Sharing Services Global Corporation.

DSS, a multinational company operating nine business divisions through strategic acquisitions and development to build shareholder value through periodic spinoffs, today announced its financial results for the first quarter 2023. "We are very pleased by the company's progress in substantially reducing our operating costs and continuing to optimize our businesses towards profitability," said Todd Macko, CFO of DSS. "Our Premier Packaging division had a stellar quarter in booking a 72% increase in revenues in the first quarter compared to the first quarter of 2022 as a result of our capital investments completed over the past year."

To view the full press release, visit https://ibn.fm/2BQl2

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed the day's trading session at $1.01, up 23.17%, on 276,351 volume with 217 trades. The average volume for the last 3 months is 279,074 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.